Respiratory Diseases

Data on adults aged 60 years and older who received a single dose of the RSV vaccine indicate safety and reactogenicity consistent with the overall GSK phase 3 trial program.

Your daily dose of the clinical news you may have missed.

Albuterol/budesonide (Airsupra) has now proven effective as novel combination as-needed rescue medication for adults with asthma regardless of disease severity.

Older adults hospitalized with RSV were older, more frail, and more likely to have respiratory comorbidities than those with influenza A or B, the study found.

Surya Bhatt, MD, MSPH, is coprincipal investigator for the 2 pivotal phase 3 clinical trials that supported today's landmark FDA approval of dupilumab for COPD.

Dupilumab represents the first new treatment approach for uncontrolled COPD in more than a decade and reduced disease exacerbations by 34% in clinical trials.

The positive pivotal phase 3 trial results showed improved lung function with neradomilast vs placebo and will support BI's US and global NDA submissions.

The approval makes dupilumab available to treat uncontrolled CRSwNP in adolescents aged 12 to 17 years, expanding on the current approved range of 18 years and older.

RSVPreF induced strong neutralizing responses in immunocompromised adults aged 18 years and older in substudy B of the ongoing phase 3 MONET clinical trial.

Patients largely underestimate how long a cold should last and the lingering symptoms too often prompt a request for antibiotics. Primary care, please resist!